Stratification of Nucleoside Analog Chemotherapy Using 1-(2′-Deoxy-2′-18F-Fluoro-β-d-Arabinofuranosyl)Cytosine and 1-(2′-Deoxy-2′-18F-Fluoro-β-l-Arabinofuranosyl)-5-Methylcytosine PET
| Autor: | Nagichettiar Satyamurthy, Dean O. Campbell, Caius G. Radu, Jason T. Lee, Johannes Czernin |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Fluorine Radioisotopes
medicine.medical_treatment Scintigraphy Deoxycytidine Article Cytosine Mice chemistry.chemical_compound Breast cancer Adenine nucleotide Cell Line Tumor Cytidine Deaminase Deoxycytidine Kinase medicine Animals Clofarabine Radiology Nuclear Medicine and imaging Chemotherapy medicine.diagnostic_test Adenine Nucleotides business.industry Cytarabine medicine.disease Gemcitabine Leukemia Lymphoid Gene Expression Regulation Neoplastic Treatment Outcome chemistry Positron emission tomography Positron-Emission Tomography Immunology Arabinonucleosides business Nuclear medicine medicine.drug |
| Zdroj: | Journal of Nuclear Medicine. 53:275-280 |
| ISSN: | 2159-662X 0161-5505 |
| DOI: | 10.2967/jnumed.111.090407 |
| Popis: | The ability to measure tumor determinants of response to nucleoside analog (NA) chemotherapy agents such as gemcitabine and related compounds could significantly affect the management of several types of cancer. Previously we showed that the accumulation in tumors of the new PET tracer 1-(2'-deoxy-2'-(18)F-fluoro-β-d-arabinofuranosyl)cytosine ((18)F-FAC) is predictive of responses to gemcitabine. (18)F-FAC retention in cells requires deoxycytidine kinase (dCK), a rate-limiting enzyme in the deoxyribonucleoside salvage metabolism and in gemcitabine conversion from an inactive prodrug to a cytotoxic compound. The objectives of the current study were to determine whether (18)F-FAC tumor uptake is also influenced by cytidine deaminase (CDA), a determinant of resistance to gemcitabine; to develop a new PET assay using (18)F-FAC and the related probe 1-(2'-deoxy-2'-(18)F-fluoro-β-l-arabinofuranosyl)-5-methylcytosine (l-(18)F-FMAC) to profile tumor lesions for both dCK and CDA enzymatic activities; and to determine whether this PET assay can identify the most effective NA chemotherapy against tumors with differential expression of dCK and CDA.Isogenic murine leukemic cell lines with defined dCK and CDA activities were generated by retroviral transduction. A cell viability assay was used to determine the sensitivity of the isogenic cell lines to the dCK-dependent NA prodrugs gemcitabine and clofarabine. In vitro enzymatic and cell-based tracer uptake assays and in vivo PET with (18)F-FAC and l-(18)F-FMAC were used to predict tumor responses to gemcitabine and clofarabine.dCK and CDA activities measured by kinase and tracer uptake assays correlated with the sensitivity of isogenic cell lines to gemcitabine and clofarabine. Coexpression of CDA decreased the sensitivity of dCK-positive cells to gemcitabine treatment in vitro by 15-fold but did not affect responses to clofarabine. Coexpression of CDA decreased (18)F-FAC but not l-(18)F-FMAC, phosphorylation, and uptake by dCK-positive cells. (18)F-FAC and l-(18)F-FMAC PET estimates of the enzymatic activities of dCK and CDA in tumor implants in mice were predictive of responses to gemcitabine and clofarabine treatment in vivo.These findings support the utility of PET-based phenotyping of tumor nucleoside metabolism for guiding the selection of NA prodrugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|